For example, obefazimod (ABX464), a small molecule that modulates the splicing of lncRNA 0599-205 to enhance miR-124 expression [113], has shown efficacy in late-phase clinical trials for ulcerative colitis, leading to suppression of IL-6 and IL-17A pathways [114,115]. The gene discussed is IL17A; the disease is ulcerative colitis.